GARNET: High SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection [Abstract 163]

Welzel TM, Zeuzem S, Dumas EO, et al. GARNET: High SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection [Abstract 163]. In New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016. Paris; 2016.

Publication Type:

Conference Paper

Source:

New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016, Number 163, Paris (2016)

Abstract:

Abstact 163

Top